Learned serum-marker combinations improve internal melanoma progression classification
Source check: Source checked. Not independent scientific confirmation.
Finding: In 323 early-stage melanoma patients, classifiers combined serum IL-4, GM-CSF and dermcidin with tumor thickness to distinguish subsequent metastatic progression. Nested internal validation supported added discrimination beyond thickness alone; this does not establish clinical benefit or external validity.
Technology: Regularized logistic regression; support vector machine; decision tree; naive Bayes; nearest neighbors
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Learned multivariable classifiers link measured circulating markers and tumor thickness to subsequent clinical outcomes.
- Test and result
- Classifiers were assessed with nested cross-validation in a clinical cohort with 74 metastatic outcomes. Scaling, oversampling, feature selection and tuning were assigned to the inner loop.
- Limitation / still unknown
- Internal validation only; unequal follow-up and incomplete sentinel-node information limit interpretation. This is postoperative risk classification, not diagnosis-time screening or an intervention benefit. Publisher first-online June 2 differs from the June 24 date in primary indexing metadata; the publisher date represents this journal version.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.12732
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary publisher front date and safe clinical/statistical Methods and Results. Operational assay sections are outside the represented evidence..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.